Research indicates that TRIM21/Ro52 contributes to the pathology of pSS and cancer, with increased expression levels linked to improved survival outcomes in certain cancer types, including diffuse large B-cell lymphoma (DLBCL), breast cancer, and renal cell carcinoma [20,21,22]. This evidence concerns the gene TRIM21 and breast cancer.